CN102470139A - 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法 - Google Patents

用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法 Download PDF

Info

Publication number
CN102470139A
CN102470139A CN2010800298152A CN201080029815A CN102470139A CN 102470139 A CN102470139 A CN 102470139A CN 2010800298152 A CN2010800298152 A CN 2010800298152A CN 201080029815 A CN201080029815 A CN 201080029815A CN 102470139 A CN102470139 A CN 102470139A
Authority
CN
China
Prior art keywords
compositions
finafloxacin
ear
nasha
star
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800298152A
Other languages
English (en)
Chinese (zh)
Inventor
D·W·斯托曼
M·A·寇翰
K·C·阿佩尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Research LLC
Original Assignee
Alcon Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42752088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102470139(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Research LLC filed Critical Alcon Research LLC
Priority to CN201610096682.XA priority Critical patent/CN105687111A/zh
Publication of CN102470139A publication Critical patent/CN102470139A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2010800298152A 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法 Pending CN102470139A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610096682.XA CN105687111A (zh) 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22262509P 2009-07-02 2009-07-02
US61/222,625 2009-07-02
PCT/US2010/040956 WO2011003091A1 (en) 2009-07-02 2010-07-02 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610096682.XA Division CN105687111A (zh) 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法

Publications (1)

Publication Number Publication Date
CN102470139A true CN102470139A (zh) 2012-05-23

Family

ID=42752088

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800298152A Pending CN102470139A (zh) 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法
CN201610096682.XA Pending CN105687111A (zh) 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610096682.XA Pending CN105687111A (zh) 2009-07-02 2010-07-02 用于治疗眼、耳或鼻感染的包含非那沙星的组合物和方法

Country Status (17)

Country Link
US (3) US8536167B2 (enExample)
EP (1) EP2448587B1 (enExample)
JP (2) JP5784012B2 (enExample)
KR (1) KR101541823B1 (enExample)
CN (2) CN102470139A (enExample)
AR (1) AR077372A1 (enExample)
AU (1) AU2010266120B2 (enExample)
BR (1) BRPI1016257B8 (enExample)
CA (1) CA2765852C (enExample)
CL (1) CL2011003327A1 (enExample)
ES (1) ES2694775T3 (enExample)
MX (1) MX2012000136A (enExample)
RU (1) RU2570731C2 (enExample)
TW (1) TWI460181B (enExample)
UY (1) UY32758A (enExample)
WO (1) WO2011003091A1 (enExample)
ZA (1) ZA201109492B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358131A (zh) * 2013-08-12 2016-02-24 诺华股份有限公司 用于治疗鼓膜造孔插管放置后的耳部感染的方法
CN107106486A (zh) * 2014-11-03 2017-08-29 鱼尾狮制药私人投资有限公司 含有非那沙星和Tris的组合物
CN109908081A (zh) * 2012-12-06 2019-06-21 鱼尾狮制药私人有限公司 非那沙星混悬液组合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8536167B2 (en) * 2009-07-02 2013-09-17 Alcon Research, Ltd. Methods for treating ophthalmic, otic, or nasal infections
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
EP3517541B1 (en) 2012-05-08 2020-07-15 Nicox Ophthalmics, Inc. Polymorphic form of fluticasone propionate
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
DE102015100068A1 (de) 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen
US11529309B2 (en) * 2016-04-29 2022-12-20 University Of Houston System Compositions, methods and kits for treating a contact lens
US10282607B2 (en) 2016-10-28 2019-05-07 The Nielsen Company (Us), Llc Reducing scale estimate errors in shelf images

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089496A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US6156728A (en) 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
DE19652239A1 (de) 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
JP2006289070A (ja) * 2005-03-18 2006-10-26 Santen Pharmaceut Co Ltd キノロン系抗菌化合物含有製品
KR101488402B1 (ko) * 2005-05-18 2015-02-03 엠펙스 파마슈티컬즈, 인코포레이티드 에어로졸화된 플루오로퀴놀론 및 이의 용도
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
US8536167B2 (en) * 2009-07-02 2013-09-17 Alcon Research, Ltd. Methods for treating ophthalmic, otic, or nasal infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089496A2 (en) * 2000-05-19 2001-11-29 Alcon Laboratories, Inc. Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
《European Helicobacter Study Group》 20070922 A. J. Bishop，et al Finafloxacin HCl - a novel experimental fluoroquinolone with monotherapeutic potential for Helicobacter pylori eradication 8-19 , *
A. J. BISHOP，ET AL: "Finafloxacin HCl - a novel experimental fluoroquinolone with monotherapeutic potential for Helicobacter pylori eradication", 《EUROPEAN HELICOBACTER STUDY GROUP》, 22 September 2007 (2007-09-22) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109908081A (zh) * 2012-12-06 2019-06-21 鱼尾狮制药私人有限公司 非那沙星混悬液组合物
CN105358131A (zh) * 2013-08-12 2016-02-24 诺华股份有限公司 用于治疗鼓膜造孔插管放置后的耳部感染的方法
CN107106486A (zh) * 2014-11-03 2017-08-29 鱼尾狮制药私人投资有限公司 含有非那沙星和Tris的组合物
CN107106486B (zh) * 2014-11-03 2021-03-23 鱼尾狮制药有限责任公司 含有非那沙星和Tris的组合物

Also Published As

Publication number Publication date
CL2011003327A1 (es) 2013-01-25
US8536167B2 (en) 2013-09-17
CA2765852A1 (en) 2011-01-06
US9993483B2 (en) 2018-06-12
BRPI1016257B1 (pt) 2021-03-16
ES2694775T3 (es) 2018-12-27
TWI460181B (zh) 2014-11-11
AR077372A1 (es) 2011-08-24
AU2010266120A1 (en) 2012-02-02
RU2012103458A (ru) 2013-08-10
ZA201109492B (en) 2013-03-27
EP2448587A1 (en) 2012-05-09
EP2448587B1 (en) 2018-08-22
CN105687111A (zh) 2016-06-22
JP2015134827A (ja) 2015-07-27
CA2765852C (en) 2014-08-26
BRPI1016257B8 (pt) 2021-05-25
JP2012532115A (ja) 2012-12-13
RU2570731C2 (ru) 2015-12-10
WO2011003091A1 (en) 2011-01-06
MX2012000136A (es) 2012-02-08
UY32758A (es) 2010-10-29
KR101541823B1 (ko) 2015-08-04
US9119859B2 (en) 2015-09-01
BRPI1016257A2 (pt) 2016-07-12
KR20120114211A (ko) 2012-10-16
US20150328229A1 (en) 2015-11-19
AU2010266120B2 (en) 2014-02-06
US20130331385A1 (en) 2013-12-12
TW201102395A (en) 2011-01-16
JP5784012B2 (ja) 2015-09-24
US20110003803A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
US9993483B2 (en) Compositions and methods for treating ophthalmic, octic, or nasal infections
CN100374114C (zh) 治疗眼、耳和鼻的抗生素组合物
US20180008611A1 (en) Method for treating otic infections after tympanostomy tube placement
US9504691B2 (en) Finafloxacin suspension compositions
US20170333441A1 (en) Compositions for treating microbial infections

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120523